Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]

This article refers to:

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S. Int J Chron Obstruct Pulmon Dis. 2020;15:995–1004.

The authors have advised there is an error in Figure 4B on page 1000. For EXACT-RS responder rates, the OR for both genders are shown to be significant at p<0.05; however, the OR is significant only in males. The correct Figure 4 is shown below.

Figure 4 Pooled analysis of (A) SGRQ responder rates, (B) EXACT-RS responder rates at 12 weeks, by gender (ITT population).

Note: *p<0.05 vs placebo.

Abbreviations: BID, twice daily; CI, confidence interval; EXACT-RS, EXAcerbations of COPD Tool-Respiratory Symptoms; GLY, nebulized glycopyrrolate; ITT, intent-to-treat; OR, odds ratio; SGRQ, St George’s Respiratory Questionnaire.

The authors apologize for this error.